Key result
Short dual antiplatelet therapy (≤ 3 months) did not increase the risk of stent thrombosis but reduced bleeding compared to prolonged therapy.
Why the study?
The optimal duration of DAPT after DES implantation remains an ongoing debate and novel data has emerged.
Does short DAPT duration improve outcomes compared to control DAPT duration in patients after drug-eluting stent implantation?
Meta-Analysis (n=41,864)
Does short DAPT duration improve outcomes compared to control DAPT duration in patients after drug-eluting stent implantation?
This meta-analysis aims to evaluate the optimal duration of DAPT after DES implantation and the role of subsequent SAPT with aspirin or a P2Y12 inhibitor.
Answers are grounded in this paper and cite their sources.
Short DAPT ≤3 months post-DES may reduce bleeding without excess thrombosis; extends RCT evidence on SAPT de-escalation.
Aim: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is an ongoing debate and novel data has emerged. The aim of this meta-analysis was to assess outcomes of short vs. control DAPT duration. In addition, the role of single antiplatelet therapy (SAPT) after DAPT with either aspirin or P2Y12 inhibitor monotherapy was analyzed.
No takes yet. Share an insight, caveat, or question.
Lahu et al. (2021) conducted a meta-analysis in Coronary artery disease (n=41,864). Short dual antiplatelet therapy (≤ 3 months) vs. Prolonged dual antiplatelet therapy (≥ 6 months) was evaluated on Definite or probable stent thrombosis (HR 1.17, 95% CI 0.89-1.54, p=0.26). Short dual antiplatelet therapy (≤ 3 months) did not increase the risk of stent thrombosis but reduced bleeding compared to prolonged therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: